FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, in particular to a cell for measuring activity of botulinum toxin, overexpressing SEPTIN2 or thioredoxin (TXN). Also disclosed is a method for measuring endopeptidase activity of botulinum toxin using said cell and a set for measuring activity of botulinum toxin containing said cell.
EFFECT: invention is effective for measuring activity of botulinum toxin by determining the degree of splitting SNAP-25.
6 cl, 15 dwg, 5 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS SPECIFICALLY BINDING TO BOTULINUM NEUROTOXIN TYPE A, AND METHOD OF USING THEM FOR THERAPY OR EMERGENCY PREVENTION OF INTOXICATION CAUSED BY BOTULINUM NEUROTOXIN TYPE A | 2021 |
|
RU2766348C1 |
| COMBINED COMPOSITION CONTAINING FGF-18 COMPOUND | 2016 |
|
RU2745453C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| ANTI-CD79B ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2817143C2 |
| AGENT FOR INHIBITING IRON ABSORPTION BY CELLS | 2019 |
|
RU2817146C2 |
| EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS WITH PROTECTIVE PROPERTIES AGAINST INTOXICATION CAUSED BY BOTULINUM NEUROTOXIN TYPE A | 2021 |
|
RU2768044C1 |
| MOLECULES BINDING WITH CD38 AND PD-L1 | 2017 |
|
RU2764201C2 |
| NK CELL LINE EXPRESSING PSMA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND SECRETING CD47/SIRPA INTERACTION BLOCKER | 2020 |
|
RU2757353C1 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
| ANTI-HLA-G ANTIBODIES AND THEIR USE | 2019 |
|
RU2797724C2 |
